Multaq
Marketed by:
sanofi-aventis (Bridgewater, NJ)
Indication:
The FDA recently approved Multaq (dronedarone) 400-mg tablets. Multaq is an antiarrhythmic indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors (ie, age >70, hypertension, diabetes, prior cerebrovascular accident, left atrial diameter ≥50 mm, or left ventricular ejection fraction <40%), who are in sinus rhythm or who will be cardioverted. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.
Dosage Form:
Tablets: 400 mg
For More Information:
http://products.sanofi-aventis.us/Multaq/Multaq.pdf
www.sanofi-aventis.us
 
 
 
 

Lamictal ODT
Marketed by:
GlaxoSmithKline (Philadelphia, PA)
Indication:
The FDA approved Lamictal ODT (lamotrigine) orally disintegrating tablets, which use a novel drug-delivery formulation to provide Lamictal in a pleasant-tasting tablet that disintegrates on the tongue. It is indicated for the long-term treatment of bipolar I disorder to lengthen the time between mood episodes in individuals aged 18 years or older who have been treated for mood disorders with other medications. Lamictal ODT is also used in combination with other medicines to treat certain types of seizures in patients aged 2 years or older, or alone when changing from other medicines used to treat partial seizures in individuals aged 16 years or older.
Dosage Form:
Orally disintegrating tablets: 25, 50, 100, and 200 mg
For More Information:
www.lamictal.com
 
 

AZOR 
Marketed by:
Daiichi Sankyo, Inc (Parsippany, NJ)
Indication:
AZOR (amlodipine and olmesartan medoxomil) has been approved by the FDA as initial or first-line therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals. The drug provides a once-daily, single-tablet combination of amlodipine, which inhibits the entrance of calcium into the blood vessel walls, with olmesartan medoxomil, the active ingredient in Benicar, which blocks angiotensin II receptors. Current US guidelines call for prescribing combination drugs as initial therapy for patients likely to require multiple drugs.
Dosage Form:
Tablets: 5/20 mg; 10/20 mg; 5/40 mg; and 10/40 mg
For More Information:
www.azor.com
 

 
Cambia 
Marketed by:
Kowa Pharmaceuticals America, Inc (Montgomery, AL)
Indication:
Kowa Pharmaceuticals America, Inc (KPA) has announced the FDA approval of Cambia (diclofenac potassium for oral solution), a nonsteroidal anti-inflammatory drug, for the treatment of acute migraine with or without aura in adults. Formulated with KPA's patented Dynamic Buffering Technology, Cambia also has been shown through clinical trials to be effective in treating the photophobia, phonophobia, and nausea commonly associated with migraines. Onset of relief occurs within 15 to 30 minutes of taking Cambia.
Dosage Form:
Packets: each containing buffered diclofenac potassium 50 mg in a soluble powder
For More Information:
www.kowapharma.com
